Epitalon vs Epithalon: Same Peptide, Different Spelling—or a Different Material?

A buyer asks for an Epitalon quotation. One supplier replies with Epithalon, another writes Epithalone, and a third attaches a paper about Epithalamin. The names look close enough to merge into one spreadsheet row. That is precisely where a procurement error can begin.

The short answer is: Epitalon, Epithalon and Epithalone are commonly used as alternate names for the synthetic tetrapeptide Ala–Glu–Asp–Gly, abbreviated AEDG. Epithalamin is not simply another spelling. It refers to a complex pineal-gland peptide extract rather than one defined four-amino-acid molecule.[1]

That answer resolves the headline question, but it is not yet a complete purchase specification. A name can still hide differences in sequence order, terminal form, counterion, nominal content, purity method and assay. Wholesale buyers should compare identity records, not just product titles.

This guide is for B2B research-material procurement. It does not provide a human protocol, dose, injection method or longevity recommendation.

What the published literature calls Epitalon

A 2025 review devoted to Epitalon states that Epitalon, Epithalon and Epithalone are names used for the tetrapeptide Ala–Glu–Asp–Gly (AEDG).[1] Earlier experimental papers also identify Epitalon as AEDG, including work on gene expression and cell models.[2,3]

The four-letter abbreviation is useful because it forces the sequence into view:

Sequence order matters. AEDG is not interchangeable with a four-amino-acid material containing the same letters in another order. Nor does the name alone establish whether the molecule has free or modified termini, whether a salt is present, or which analytical result supports identity.

This is why a buyer should not settle a naming dispute by counting Google results. The defensible question is: Does the supplier define the quoted material as Ala–Glu–Asp–Gly, and do the batch documents consistently support that identity?

Epithalamin is the important look-alike name

Epithalamin predates the synthetic tetrapeptide. The literature describes it as a peptide preparation or polypeptide extract derived from bovine pineal tissue, whereas Epitalon is the defined synthetic tetrapeptide developed from research around that extract.[1,4]

That distinction changes how evidence should be read. A study performed with a complex extract cannot automatically establish an effect, specification or dose for one purified AEDG molecule. Conversely, a cell experiment using synthetic AEDG does not characterise all components of Epithalamin.

The confusion persists because articles and online discussions sometimes move between the two names while discussing pineal peptides, aging or melatonin. A buyer can prevent the mix-up by keeping two separate fields in the evidence table:

For MY PEPTIDE’s catalogue, the relevant Epithalon research-material page should be treated as a request for the defined product listed there—not as a reference to Epithalamin. Current identity and batch documentation still need confirmation in the quotation.

Why alternate spelling still deserves a written specification

If the literature recognises the spellings as aliases, why not accept any label? Because commercial records need consistency across the entire chain:

• catalogue entry;
• quotation;
• purchase order;
• vial label;
• batch record;
• certificate or test report;
• external laboratory submission;
• complaint or replacement record.

Suppose a quotation says Epitalon, the vial says Epithalon and the report says only AEDG. Those three terms may point to the same intended sequence, but the connection should be explicit. Otherwise, a later reviewer has to infer that the records belong together.

A practical master name is:

Epitalon (also called Epithalon/Epithalone), sequence Ala–Glu–Asp–Gly (AEDG)

The exact punctuation is not important. The stable identity is. Preserve the supplier’s original wording as an alias, but require one master specification to follow the batch.

The sequence alone may still be incomplete

“AEDG” is a strong starting point, not the end of due diligence. A four-residue peptide can still be described incompletely if the supplier does not state:

1. Sequence direction. Peptide sequences are conventionally written from the N-terminus to the C-terminus; the record should make that convention unambiguous.
2. Terminal form. A free acid and an amidated or otherwise modified terminus are not automatically the same material.
3. Additional modification. “N-acetyl,” “amidated” or another derivative should not be silently folded into ordinary Epitalon.
4. Salt or counterion. If the material is supplied as a salt, that information belongs in the specification and mass interpretation.
5. Nominal content. Milligrams per vial are not the same measurement as chromatographic purity.
6. Analytical identity. A retention-time match alone can be useful but is stronger when supported by an orthogonal identity method such as mass spectrometry.

The 2025 review also notes that published depictions have not always been chemically uniform: one cited article represented the same amino acids with different linkage positions.[1] That observation is another reason to ask for a precise structural definition instead of assuming every diagram carrying the name is equivalent.

Purity, identity and content answer different questions

A supplier may send an HPLC result showing a high area percentage. That result can speak to chromatographic purity under the stated method. It does not, by itself, prove that the main peak is AEDG or that the vial contains the labelled number of milligrams.

For a small tetrapeptide, a coherent batch package separates:

• identity: does the measured material match the intended AEDG structure or expected mass?
• purity: what proportion of detected chromatographic material appears as the principal component under the method?
• content or assay: how much intended material is present per vial or sample mass?
• related substances: what known or unknown impurities are detected and how are they reported?
• physical specification: what appearance and packaging criteria were applied at release?

This separation matters when comparing suppliers. A line reading “Epithalon 99% — 10 mg” contains two different claims. The 99% figure does not prove the 10 mg figure, and neither number defines the sequence unless the identity is documented.

A buyer’s quote-comparison example

Imagine three price-list rows:

Rows A and B may become comparable after the suppliers confirm the same AEDG specification. Row C should remain separate unless the buyer actually intends to source an extract and has an extract-specific quality plan.

Sorting by price before resolving identity creates a false comparison. The lowest quote may represent a different material, a different terminal form or a headline content figure unsupported by a quantitative result.

What to put in an Epitalon RFQ

For a wholesale enquiry, request the material as a complete specification rather than a single product word:

Please quote Epitalon / Epithalon, sequence Ala–Glu–Asp–Gly (AEDG). Confirm the sequence direction, terminal form, any modification, salt or counterion, nominal content per vial, vials per kit, chromatographic purity method, quantitative content method, orthogonal identity evidence and available batch-linked documentation. Do not substitute Epithalamin or another pineal extract.

MY PEPTIDE’s confirmed wholesale rule is one kit per peptide as the minimum, with ten vials of the same product in each kit. A single order may contain one full kit of product A and one full kit of product B, but not five vials of each combined as one kit. Current details are on the MY PEPTIDE Wholesale Terms page.

If different nominal contents are requested for the same peptide, ask how the minimum applies to each specification. The quotation is based on product name, nominal content and quantity; prices are not displayed publicly.

Red flags in documents and listings

Treat the following as clarification triggers, not automatic proof of fraud:

• The catalogue says Epitalon, but the report is for Epithalamin.
• The supplier describes Epithalamin as merely a longer spelling of Epitalon.
• The document gives only “AEDG” without sequence direction, terminal form or batch number.
• A modified version is marketed under the plain name without disclosing the modification.
• The HPLC purity percentage is presented as proof of identity and fill amount.
• The report, label and invoice use different names and the supplier will not provide a written cross-reference.
• A supplier cites an Epithalamin human-outcome paper as direct proof of a synthetic AEDG product claim.

Each mismatch has a possible innocent explanation—translation, legacy naming, abbreviated labels or document design—but the explanation needs to be written and batch-linked before ordering.

How to read research without merging the materials

Published Epitalon research spans cell systems, animal models and a smaller body of human-related literature. The 2025 overview is useful for tracing terminology and the sequence, but its broad “promising properties” language is not a licence to convert all preclinical findings into human benefits.[1] Individual experimental papers should be read according to their actual material, model and endpoint.[2,3]

The first identity check in any paper is therefore:

1. Does the methods section say Epitalon/Epithalon, AEDG or Epithalamin?
2. Is the studied material a defined synthetic tetrapeptide or an extract?
3. Is the exact sequence or preparation described?
4. Is the experiment in vitro, animal or human?
5. Does the outcome support the claim being made—or only a narrower biomarker or laboratory observation?

This prevents a common evidence shortcut: using a similar name to bridge from one material and study type to another.

FAQ

Are Epitalon and Epithalon the same peptide?

In mainstream published usage, yes: both names, along with Epithalone, commonly refer to the AEDG tetrapeptide Ala–Glu–Asp–Gly.[1] A buyer should still confirm sequence, termini, modifications and counterion in writing.

Is Epithalamin the same as Epitalon?

No. Epithalamin is described as a complex pineal peptide extract or preparation, while Epitalon is a defined synthetic tetrapeptide developed from research around that extract.[1,4]

Does “99% purity” confirm that a vial is Epitalon?

Not by itself. Chromatographic purity, molecular identity and quantitative vial content are separate questions. The batch package should state the methods and connect every result to the shipped lot.

Which spelling should appear on a purchase order?

Use one master name plus the aliases and sequence, for example: “Epitalon (Epithalon/Epithalone), Ala–Glu–Asp–Gly, AEDG.” Then add terminal form, modification, counterion, content and batch-document requirements.

The practical conclusion

The naming problem has a simple centre: Epitalon, Epithalon and Epithalone usually point to the same defined AEDG tetrapeptide; Epithalamin does not. The procurement problem is broader. Buyers must carry the same exact identity through quotation, label, batch file and laboratory submission, while keeping sequence, termini, counterion, purity and content in separate fields.

That discipline prevents a spelling variation from becoming a material substitution—and stops research on a complex extract from being presented as direct evidence for a synthetic tetrapeptide.

For current B2B availability and documentation, contact service@wholesalepeptide.xyz.

References

1. Araj S, Wiśniewska RJ, Sałaga M. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025;26(6):2605. PubMed PMID: 40141333 · Full text.
2. Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781–791. Background identity references for AEDG/Epitalon are synthesised in Reference 1; claims should be checked against the exact paper and model.
3. Linkova NS, Khavinson VKh, Polyakova VO, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules. 2020;25(3):609. Full text.
4. Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger; 2005. Historical distinction between Epithalamin preparations and synthetic short peptides is reviewed in Reference 1.

Community observations used only for query language

• Reddit discussions show recurring confusion among Epitalon, Epithalon and Epithalamin, including claims that the names imply different protocols. These posts are used only to document buyer vocabulary and confusion; dosing and use instructions are excluded. Example discussion · Example naming discussion.

Editorial and evidence note

This is a B2B procurement and identity guide, not a treatment guide. It contains no customer case, MY PEPTIDE batch result or fabricated laboratory data. The article was prepared with AI assistance and source checking by the MY PEPTIDE Editorial Team; no independent laboratory or clinical expert review is claimed. Research use only; not medical advice.